Research Triangle Park drug-development startup T3D Therapeutics has received a $1.8 million federal grant to further the development of its experimental treatment for Alzheimer’s disease.
The Small Business Innovation Research grant announced Tuesday will be used to support Phase 2a clinical trial of T3D-959. That trial is expected to involve 36 patients with mild-to-moderate cases of Alzheimer’s.
T3D-959 has demonstrated encouraging results in experiments with lab rats that hold out the promise that it could slow or even halt the progress of Alzheimer’s, said CEO John Didsbury. Among other things, rats treated with the drug have shown improved memory and motor function.
“This is a really compelling new approach for Alzheimer’s disease,” Didsbury said.
Alzheimer’s has bedeviled researchers because it involves multiple “defects,” or physiological issues. But the test data in rats indicates that T3D-959 addresses multiple defects, Didsbury said.
Founded in 2013, T3D is a virtual company that relies on outsourcing. It currently has two full-time and one-part time employee.
T3D-959 was licensed in 2013 from Raleigh’s Dara BioSciences, where Didsbury previously was chief scientific officer.
“Dara changed its businss model from R&D to sales and marketing,” Disbury said. “It was no longer a strategic fit for them.”